Nifuran

Quick links to important sections

Nifuran

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nifuran

Defining Nifuran: Classification and Active Ingredient

Property Description
Active ingredient Nitrofurantoin
Form Oral dosage forms (tablets, capsules)
Pharmacological class Antimicrobial agent (Nitrofuran derivative)
Common use Urinary antiseptic
Origin Synthetic

Nifuran is a medicinal product containing the active substance Nitrofurantoin, which is a synthetic compound classified as an antimicrobial agent used specifically against bacteria. This substance belongs to the Nitrofuran derivative chemical class, a group of molecules engineered for their biological function. Pharmacological data describes its utility in its designated therapeutic area.

The active ingredient is formulated as a single-ingredient medicine intended for oral dosage forms, typically supplied as tablets or various types of capsules. Unlike many older antibiotics, Nitrofurantoin is often manufactured in specialized macro-crystalline forms to promote optimal absorption kinetics. As a classified antibiotic, this medication requires a prescription and is recognized by the World Health Organization (WHO) as an Essential Medicine.

Nifuran's Purpose and Targeted Antimicrobial Action

The overall general purpose of Nifuran is to provide a specialized method for eliminating bacterial populations concentrated within the urinary system. The substance functions as a urinary antiseptic because its efficacy is achieved by concentrating rapidly and in high levels in the urine, rather than circulating broadly in the bloodstream. This localized concentration is a differentiating factor, as clinical experience has shown it helps maintain the balance of beneficial bacteria elsewhere in the body.

The mechanism is characterized by dual-action strength: the drug is effective as both a bacteriostatic agent—stopping the bacteria from growing and multiplying—and a bactericidal agent—actively killing the established pathogens. This highly targeted activity helps ensure a thorough clearance of the bacterial cause of common urinary problems, such as acute uncomplicated cystitis.

Regulatory References

  1. World Health Organization
  2. WHO Essential Medicines List

What side effects are possible with Nifuran?

Possible Side Effects and Safety Information

The regulatory safety profile for Nitrofurantoin (Nifuran) outlines adverse reactions grouped by frequency and affected physiological systems, as documented by official government health authorities.


Adverse Reaction Classifications

Side effects are categorized based on incidence, ranging from common gastrointestinal upset to rare, clinically significant reactions.

Classification Examples of Reactions (SOC)
Common Nausea, vomiting, headache, flatulence, diarrhea (Gastrointestinal, Nervous System)
Rare Peripheral neuropathy, cholestatic jaundice, hemolytic anemia (Nervous System, Hepatobiliary, Blood)

Serious Adverse Reactions and Systemic Effects

The label-documented serious adverse reactions include pulmonary toxicity (acute, subacute, and chronic forms), potentially irreversible peripheral neuropathy, and severe hepatotoxicity (e.g., hepatitis). These events primarily affect the Respiratory, Nervous, and Hepatobiliary systems.

Exposure-Related Patterns

The likelihood of certain adverse reactions is officially linked to treatment duration. Acute pulmonary reactions typically occur within the first week of treatment, while chronic pulmonary reactions and chronic active hepatitis are usually associated with continuous, long-term use (six months or more).


Population-Specific Safety Constraints

Specific patient populations have safety constraints explicitly noted in regulatory documents:

  • Renal Impairment: The drug is contraindicated in individuals with severe impairment of renal function (e.g., creatinine clearance below 60 mL/min) due to the increased risk of toxicity.
  • Pregnancy/Infants: It is contraindicated in pregnant patients at term (38-42 weeks) and in infants under one month of age, due to the potential risk of hemolytic anemia.

The official labeling also notes that the urine may change color to yellow or brown during therapy.

Overdose and Emergency Response

️ Overdose and When to Seek Help

Overdosage of Nifuran (nitrofurantoin) can lead to certain physiological manifestations, and immediate action is required. Factual information from regulatory sources indicates that excessive oral intake is primarily associated with emesis (vomiting) due to the irritating nature of the drug.

Clinical Manifestations and Emergency Action

Overdose Presentation Key Management Goal Specific Action Required (Labeling)
Excessive oral intake leading to vomiting (emesis) Promote urinary excretion of the drug. Maintain a high fluid intake.
Overdose of any nitrofurantoin formulation Gastric emptying and supportive care. Induce emesis followed by gastric lavage (for oral suspension).

No specific antidote is known for nitrofurantoin overdose; therefore, management focuses on supportive measures and removing the unabsorbed drug. The most critical instruction for overdosage of any nitrofurantoin product is to get medical help right away or contact a poison control center immediately. If the individual has collapsed, had a seizure, or is struggling to breathe, call emergency services immediately. These instructions are mandatory due to the potential for severe consequences associated with high exposure.

Therapeutic Uses of Nifuran

What Nifuran treats: main uses and benefits

Nifuran is an antibacterial medication specifically formulated to address infections within the urinary tract. Unlike broad-spectrum antibiotics that affect multiple systems in the body, its activity is primarily concentrated in the urine, making it a targeted option for localized infections.

Primary Uses

The medication is primarily used to manage two types of urinary conditions:

  • Acute Urinary Tract Infections (UTIs): It is used to treat sudden-onset infections of the bladder, commonly referred to as cystitis. It works by interfering with the vital processes of the bacteria causing the infection.
  • Prevention of Recurrent Infections: In individuals who experience frequent or chronic urinary tract infections, it may be used as a preventive measure to keep the urine free of bacterial growth over a longer period.

Spectrum of Activity

Nifuran is effective against a variety of Gram-positive and Gram-negative bacteria that are frequently responsible for urinary tract issues. This includes common pathogens such as:

  • Escherichia coli (E. coli)
  • Enterococci
  • Staphylococci
  • Klebsiella species
  • Enterobacter species

Benefits in Treatment

One of the main characteristics of this medication is its ability to reach therapeutic concentrations quickly in the bladder. Because it is filtered rapidly by the kidneys and excreted into the urine, it delivers the antibacterial agent directly to the site of the infection.

Furthermore, the development of bacterial resistance to Nifuran is relatively low compared to some other antibiotics. This is due to its complex mechanism of action, which attacks multiple bacterial targets simultaneously, making it difficult for bacteria to adapt and survive during the course of treatment.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope

Classification Eligible Population Non-Eligible Populations (Contraindicated)
Age Group Adults and pediatric patients mathbf1 month of age and older mathbfNeonates under one month of age.
Organ Function Normal renal and hepatic function Severe renal impairment (Creatinine Clearance < 60 mL/min) or history of cholestatic jaundice linked to the drug.

Nifuran (Nitrofurantoin) is strictly regulated for use, with absolute contraindications prohibiting its administration to specific patient groups, regardless of its intended use. The medicine must not be used by individuals with a known hypersensitivity to the drug or those with a history of drug-associated liver dysfunction.

Non-eligibility is also determined by physiological states. The medicine is contraindicated in pregnant patients mathbfat term (38–42 weeks gestation, labor, or delivery) due to risk to the infant. Use is mathbfnot recommended when breastfeeding infants under one month of age or infants with Glucose-6-phosphate dehydrogenase ( G6PD) deficiency.

Furthermore, the medicine is not indicated for the treatment of upper urinary tract infections, such as pyelonephritis. Caution is advised for patients with comorbidities like diabetes or anemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nifuran (Nitrofurantoin) has officially documented interaction patterns that primarily affect the drug’s concentration in the bloodstream and its antibacterial activity in the urine. All interaction information is aligned with government regulatory prescribing documents.

Pharmacokinetic and Pharmacodynamic Interactions

Substance Category Formal Interaction Outcome Mechanism Type
Uricosuric Agents (e.g., Probenecid, Sulfinpyrazone) Increases Nitrofurantoin serum exposure; decreases urinary therapeutic levels. Renal Tubular Secretion Inhibition
Antacids (Magnesium Trisilicate) Reduces rate and extent of Nitrofurantoin absorption. Gastrointestinal Absorption Alteration
Quinolone Antimicrobials Documented in vitro antagonism. Pharmacodynamic
Urine Alkalizing Agents Decreases Nitrofurantoin’s antibacterial activity. Pharmacodynamic

Interaction-Related Restrictions

Co-administration with live Oral Typhoid Vaccine is officially documented to inactivate the vaccine and is therefore restricted. The use of certain uricosuric agents like Probenecid and Sulfinpyrazone is discouraged as they inhibit renal clearance, leading to a higher potential for drug-related toxicity and reduced efficacy. Administration with food or agents that delay gastric emptying, however, officially improves the bioavailability of Nitrofurantoin. For patients with impaired renal function, the interaction with the body's clearance pathway is crucial, as reduced excretion leads to significantly increased serum exposure and toxicity risk.

Mechanism of Action

Reductive Bioactivation and Multi-Target Damage

The mechanism of action for Nitrofurantoin (Nifuran) is highly distinct, relying on a localized, multi-target destructive process within bacteria that is fundamentally restricted to the urinary system. The drug functions as a prodrug, requiring specific bacterial enzymes (nitroreductases) to convert it into highly reactive intermediates (free radicals) inside the bacterial cell. These unstable intermediates then launch a non-specific, simultaneous attack on multiple essential targets, including DNA, RNA, ribosomal proteins, and metabolic enzymes. This comprehensive, widespread damage to the pathogen's core machinery results in the functional arrest of bacterial replication and structural integrity.

Mechanistic Confinement and Constraints

The mechanism is entirely dependent on achieving high concentrations of the active molecule specifically in the urine, which dictates that its cytotoxic effects are contained within the urinary tract. This functional confinement results in insufficient exposure of the mechanism to pathogens in systemic tissues or the upper urinary tract. Furthermore, the mechanism can be rendered inert by bacterial loss-of-function mutations in the genes for the activating nitroreductase enzymes, which prevent the crucial activation step and thus prevents the activation of the mechanistic cascade.

Dosage and Administration Information

How Nifuran is Used in Clinical Practice

Nifuran is administered exclusively via the oral route, available as standard-release capsules (25 mg, 50 mg, 100 mg), prolonged-release 100 mg capsules, and an oral suspension. The dosing regimen is typically determined by the purpose of use. For acute, uncomplicated administration, the standard-release formulation is taken in doses of 50 mg to 100 mg, repeated four times daily. Conversely, the prolonged-release 100 mg capsule is often scheduled for twice-daily administration.


Administration Conditions and Timing

A key instruction for proper administration is the requirement to take the medicine with food or milk. This instruction is intended to enhance the absorption of the active ingredient and improve its tolerance in the gastrointestinal system. When using the liquid oral suspension, the bottle must be shaken well before measuring the dose, and it can be mixed with water, milk, or fruit juice. For long-term suppressive patterns, the required dosing is reduced to 50 mg to 100 mg once daily, commonly taken at bedtime.


Duration and Population Constraints

The duration of an acute course is usually seven days, though long-term suppressive use may extend up to twelve months. There are specific considerations for certain patient populations. The medicine is generally contraindicated in patients with compromised renal function, often defined by an eGFR or creatinine clearance less than 45 mL/minute. Furthermore, the medication is not approved for use in infants under one month of age, with pediatric dosing for older children being weight-based. If a dose is missed, guidance suggests taking it as soon as remembered; however, if the time is close to the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed, without taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nifuran (Nitrofurantoin)

The research evidence for Nifuran primarily consists of short-term randomized controlled trials (RCTs) and various systematic reviews and meta-analyses which summarize data from studies conducted over several decades. Research explored the medicine's role in addressing acute lower urinary tract infections and in contexts involving the reduction of recurrence risk. The evidence highlights what has been observed in study populations and also clarifies areas where data remain limited or uncertain.


Evidence for Use in Acute Uncomplicated Cystitis (AUC)

Studies exploring the use of Nifuran for uncomplicated cystitis have mostly used short-term RCTs. The populations evaluated were predominantly adult, non-pregnant women. Researchers monitored outcomes related to Clinical Cure (the resolution of symptoms) and Microbiological Cure (the eradication of the causative bacteria in urine cultures).

Findings described in clinical trials and systematic reviews reported clinical resolution measurements in the observed populations. Studies focusing on Microbiological Cure reported success measurements that varied when compared to certain other antibacterial agents. Research exploring short-term symptom changes indicated patterns of variability in measured symptom resolution when comparing 3-day regimens to longer courses.


Research on Preventing Recurrent Infections (Prophylaxis)

Research has explored the use of Nifuran in a prophylactic (preventive) context for individuals with a history of recurrent urinary tract infections (rUTI). This evidence comes from controlled trials and long-term observational cohort studies over periods of 6 to 12 months. Systematic reviews and meta-analyses explored whether antimicrobial prophylaxis was associated with a lower measured rate of recurrence when compared to a placebo or no intervention. Researchers monitored recurrence rates and reported data patterns observed in the populations when compared against other long-term antibacterial agents used for this preventive purpose.


Uncertainty and Research Gaps

The evidence quality varies across studies, particularly due to the age and methodology of many foundational trials. Data for certain groups, especially older men and frail care home residents with recurrent urinary issues, are insufficient. While research describes certain measurements of sustained activity against common pathogens, continued monitoring of resistance prevalence is ongoing and necessary, as the data are still emerging and subject to geographic variation.

Frequently Asked Questions (FAQ)

Common questions about Nifuran (FAQ)

Q: Why do people say they feel tired when they start taking Nifuran?

Official product information indicates that some people may experience drowsiness, dizziness, or asthenia (fatigue) as potential adverse reactions when taking Nifuran. If these effects occur, they are typically reported early in the treatment course.

Q: Can Nifuran affect my sleep?

The official labeling notes that drowsiness (somnolence) is a possible nervous system adverse reaction. If this effect occurs, it may influence sleep patterns.

Q: Is it true that Nifuran interacts with alcohol?

Regulatory warnings state that avoiding excessive alcohol intake may help manage associated common adverse effects such as nausea or headache.

Q: What foods or drinks should people be careful about when taking Nifuran?

No direct interactions with specific foods or drinks are documented in official sources. However, because Nifuran is used to treat urinary tract infections, some health information suggests limiting high amounts of caffeine, spicy foods, or acidic foods, as these are sometimes known to irritate the bladder and aggravate UTI symptoms.

Q: How long does it usually take for someone to feel the effects of Nifuran?

According to official patient information, the drug is formulated to act quickly within the urinary system. For most infections, clinical improvement is typically observed within a few days of starting the course of treatment.

Q: What should I do if I accidentally take more Nifuran than prescribed?

In situations involving over-ingestion and serious symptoms, regulatory guidelines indicate that emergency medical assistance is necessary. For non-severe instances of over-ingestion, official safety guidelines state that contacting a poison control center is advised.

Q: Does Nifuran have any known interactions with common over-the-counter pain relievers?

Official patient guidelines indicate that common over-the-counter pain relievers, including paracetamol (acetaminophen) and ibuprofen, are generally safe to be taken alongside Nifuran.

Q: Can Nifuran cause skin rashes or sensitivity to the sun?

The regulatory safety profile lists rare and serious dermatologic adverse reactions, such as erythema multiforme. However, official sources indicate that photosensitivity, which causes extreme sun-related rash, is not typically associated with this medication.

Q: Does Nifuran affect fertility?

Studies and official patient information state that there is no current evidence to suggest that Nifuran reduces fertility in either men or women.

Q: Is Nifuran available as a generic drug?

The medication Nifuran contains the active ingredient Nitrofurantoin. The active ingredient is listed in the USP (United States Pharmacopeia) and is widely manufactured and available as a generic medication.

Q: Can Nifuran interact with herbal supplements?

Official guidelines advise caution regarding the co-administration of herbal remedies and supplements. Since these products are not subject to the same testing as prescription medicines, official guidance emphasizes the importance of informing a healthcare provider about all concurrent medications or supplements.

Q: If I am taking Nifuran, can I still drive?

The official labeling for Nifuran states that it may cause dizziness and drowsiness as adverse effects. Official warnings state that driving or operating machinery should be avoided if an individual experiences these effects, as they may impact judgment and motor skills.

Q: If Nifuran makes me dizzy, is that a side effect that goes away?

Dizziness is listed as a potential adverse reaction of Nifuran. Official patient information indicates that nervous system effects like dizziness or headache are usually temporary in nature.

Q: Does Nifuran interact with contraceptives?

Based on systematic reviews and clinical guidelines, Nifuran does not typically reduce the effectiveness of hormonal contraceptives.

Q: If I stop taking Nifuran suddenly, are there any known issues?

Official clinical summaries note that sudden discontinuation is sometimes necessary if a serious adverse reaction, such as acute liver injury, develops. In such cases, the reaction may resolve once the medication is stopped. The specific consequences of sudden discontinuation are dependent on individual circumstances.

Q: Can Nifuran make other side effects worse?

The official warnings state that Nifuran can worsen certain pre-existing conditions, such as peripheral neuropathy (a nerve disorder). The potential for certain side effects, like nausea, may also be increased when combined with substances like alcohol.

Q: Are there any physical activities that should be avoided while taking Nifuran?

Regulatory documents do not list restrictions on general physical exercise or activity. The only noted activity restriction is related to the nervous system side effects: if the medication causes dizziness or drowsiness, activities such as driving or operating machinery should be avoided.

Q: Can Nifuran interact with caffeine?

Official drug interaction documents do not list a direct interaction between Nifuran and caffeine. However, because caffeine can sometimes irritate the bladder, some patient resources suggest limiting large amounts of caffeine as it may aggravate underlying urinary tract infection symptoms.

Q: Is Nifuran generally considered suitable for older adults?

Nifuran is officially contraindicated in patients with compromised renal (kidney) function, defined by a creatinine clearance less than 60 mL/min. Since reduced kidney function is more common in older adults, use requires careful assessment. Official warnings also note that chronic pulmonary (lung) reactions can occur in elderly patients, requiring close monitoring, particularly during long-term use.

Q: Is Nifuran safe for women who are breastfeeding?

Official patient information indicates the medication passes into breast milk in small amounts. It is generally considered acceptable when breastfeeding a healthy infant. However, regulatory documents advise against its use if the infant has jaundice or a condition called Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Q: Can Nifuran affect blood sugar levels?

Official warnings note that Nifuran can interfere with certain medical tests. Specifically, it may cause false positive results when testing urinary glucose for reducing substances. This information is relevant for patients managing diabetes who rely on such tests.

Q: Is Nifuran safe to take if I am pregnant?

Official patient information indicates that Nifuran may be taken during the first and second trimesters of pregnancy. However, regulatory documents advise against its use during the third trimester (at term) due to a potential, small risk related to the baby's red blood cells.

How should Nifuran be stored and disposed of?

Storage Conditions

Nifuran (nitrofurantoin) must be stored strictly according to official regulatory requirements to maintain its stability. The product is required to be kept in its original container, which must be tightly closed.

The medication should be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from light, moisture, and excessive heat. It is critical that the medicine be kept out of the reach and sight of children.

Disposal Instructions

Disposal of unused or expired Nifuran should preferentially occur through a drug take-back program. If this option is unavailable, the medicine must be removed from its container, mixed with an undesirable substance (such as cat litter), and placed in a sealed bag before being discarded with household trash. The product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nifuran found in:

A-Z Index: